Nan Fung Group Holdings Ltd Makes New $3.61 Million Investment in Revolution Medicines, Inc. $RVMD

Nan Fung Group Holdings Ltd bought a new position in Revolution Medicines, Inc. (NASDAQ:RVMD) during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor bought 19,253 shares of the company’s stock, valued at approximately $3,605,702. Revolution Medicines makes up approximately 0.0% of Nan Fung Group Holdings Ltd’s investment portfolio, making the stock its 10th biggest holding.

Several other hedge funds have also bought and sold shares of the business. Contravisory Investment Management Inc. purchased a new position in Revolution Medicines during the second quarter valued at $32,000. Global Retirement Partners LLC raised its stake in shares of Revolution Medicines by 1,002.8% in the 4th quarter. Global Retirement Partners LLC now owns 397 shares of the company’s stock valued at $32,000 after acquiring an additional 361 shares during the period. Torren Management LLC acquired a new position in shares of Revolution Medicines during the 4th quarter worth about $33,000. Johnson Financial Group Inc. acquired a new position in Revolution Medicines in the 2nd quarter valued at $37,000. Finally, Arax Advisory Partners purchased a new position in shares of Revolution Medicines during the fourth quarter valued at approximately $38,000. Institutional investors own 94.34% of the company’s stock.

Revolution Medicines Price Performance

Shares of RVMD traded down $13.36 during trading hours on Friday, reaching $207.79. The company had a trading volume of 1,381,467 shares, compared to its average volume of 3,013,255. The company has a market capitalization of $44.54 billion, a price-to-earnings ratio of -23.56 and a beta of 1.39. The company has a current ratio of 11.38, a quick ratio of 11.38 and a debt-to-equity ratio of 0.40. Revolution Medicines, Inc. has a 12-month low of $37.56 and a 12-month high of $224.31. The firm has a 50 day simple moving average of $192.43 and a 200-day simple moving average of $148.17.

Revolution Medicines (NASDAQ:RVMD) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($3.06) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.04) by ($1.02). During the same quarter last year, the company earned ($1.31) EPS. Research analysts expect that Revolution Medicines, Inc. will post -8.82 earnings per share for the current year.

Insider Activity at Revolution Medicines

In other news, insider Mark A. Goldsmith sold 80,000 shares of the business’s stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $209.20, for a total value of $16,736,000.00. Following the completion of the sale, the insider owned 267,330 shares of the company’s stock, valued at approximately $55,925,436. The trade was a 23.03% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, COO Margaret A. Horn sold 60,400 shares of the business’s stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $160.17, for a total value of $9,674,268.00. Following the sale, the chief operating officer owned 158,222 shares of the company’s stock, valued at approximately $25,342,417.74. This represents a 27.63% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 212,497 shares of company stock valued at $38,206,486 in the last 90 days. Corporate insiders own 7.60% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the stock. Sanford C. Bernstein boosted their target price on shares of Revolution Medicines from $151.00 to $179.00 and gave the stock a “market perform” rating in a report on Friday, August 21st. Oppenheimer raised their price objective on shares of Revolution Medicines from $230.00 to $260.00 and gave the stock an “outperform” rating in a research report on Thursday. Wolfe Research reiterated an “outperform” rating and set a $220.00 price objective on shares of Revolution Medicines in a research report on Monday, August 10th. UBS Group boosted their price objective on Revolution Medicines from $220.00 to $265.00 and gave the company a “buy” rating in a research note on Friday. Finally, Needham & Company LLC boosted their price objective on shares of Revolution Medicines from $236.00 to $240.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. Two analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $198.89.

Revolution Medicines News Roundup

Here are the key news stories impacting Revolution Medicines this week:

• Positive Sentiment: RASONQUE received an unusually rapid FDA approval—about one month after filing—for metastatic pancreatic cancer. Clinical results indicated the treatment could substantially extend patient survival, while analysts see potential peak sales of approximately $11.5 billion. Revolution Medicines FDA approval and sales potential
• Positive Sentiment: Analysts raised their valuations following the approval. Guggenheim lifted its price target to $275 from $240 and assigned a Buy rating; HC Wainwright maintained Buy with a $280 target, while Wedbush and Truist also raised their targets to $225 and $239, respectively. Analyst price-target changes
• Positive Sentiment: RBC characterized the RASONQUE launch as rapid, and Oppenheimer said the product label expands the commercial opportunity. The approval also validates Revolution Medicines’ decision to remain independent rather than accept takeover interest, allowing it to retain the product’s potential economics. RASONQUE commercial opportunity
• Neutral Sentiment: HC Wainwright projects continued losses but expects improvement, forecasting 2027 quarterly EPS of negative $2.06, negative $1.70, negative $1.62 and negative $1.47, or negative $6.86 for the full year versus a current-year consensus loss of $8.82. HC Wainwright earnings estimates
• Negative Sentiment: RASONQUE’s list price is approximately $39,800 per month, which could intensify payer, reimbursement and access concerns. Investors are also weighing the stock’s elevated valuation and the execution risk of launching a first commercial product while the company remains unprofitable. RASONQUE pricing

About Revolution Medicines

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.